- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04277663
The Study of IBI310 in Combination With IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
March 7, 2023 updated by: Innovent Biologics (Suzhou) Co. Ltd.
A Phase 3, Open-label, Multicenter Study, IBI310 in Combination With IBI308 and IBI308 Compared to High-Dose Interferon In Patients With Acral Melanoma That Has Been Removed by Surgery
This is a phase III randomized, control, multi-center study of recombinant humanized anti-PD-1 mAb in combination with CTLA4 mAb for injection compared to high-Dose interferon in patients with acral melanoma that has been removed by surgery.
Study Overview
Status
Terminated
Intervention / Treatment
Study Type
Interventional
Enrollment (Actual)
136
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Beijing, China
- Beijing Cancer Hospital
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 75 years (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Sign the written informed consent (Informed Consent, ICF), and be able to abide by the visits and related procedures stipulated in the plan.
- Completely resected stage IIIB-IV acral melanoma (according to the 8th edition of AJCC staging criteria for malignant melanoma of the skin). Complete resection of stage III melanoma includes extended resection of the primary lesion and/or regional lymph node dissection and/or resection of satellite nodules. Complete resection of stage IV melanoma includes resection of primary tumor and complete resection of metastases. Complete resection of melanoma should conform to the principle of R0 resection and be confirmed by the investigator. Requirements for regional lymph node dissection refer to: upper extremity melanoma, at least 10 lymph nodes in the draining lymph node area; lower extremity melanoma, at least 5 lymph nodes in the draining lymph node area. In special cases, such as ① the long diameter of lymph nodes is ≥ 3 cm, it is considered that the number of lymph nodes can not be resected because of lymph node fusion; ② the draining lymph node area that needs to be cleaned only includes the cubital fossa or popliteal fossa, and the number of lymph nodes is difficult to reach 5-10, etc., it needs to be studied The patient confirmed whether the lymph node dissection was in line with R0 resection.
- Stage IIIB-IV acral melanoma with histologically/cytologically confirmed primary lesions in extremities (hands, feet, subungual nails). For subjects with only metastatic lesions confirmed by histopathology, researchers need to confirm that the primary lesions are in the extremities and exclude other primary sites, and they can discuss with the medical monitors to decide whether to enroll.
- The first study drug injection can only be carried out when the incision is completely healed after melanoma resection, and the injection time should not exceed 13 weeks after the operation (if the time limit is exceeded due to unforeseen reasons, it can be discussed with the medical supervisor decision to enroll).
- Within 4 weeks before randomization, R0 complete resection was confirmed by physical examination and imaging examination.
Exclusion Criteria:
- Mucosal-derived melanoma, ocular uveal melanoma, transitional metastasis and leptomeningeal metastasis.
- Previously exposed to any anti-CTLA-4, anti-PD-1 or anti-PD-L1/2 antibodies.
- Previous use of interferon. If interferon therapy was used ≥ 1 year before the first dose of study treatment, and the treatment time was ≤ 30 days or the treatment dose was ≤ 3×106IU/d, they could be enrolled.
- Hyperthyroidism or hypothyroidism, Note: Hypothyroidism subjects with stable condition after hormone replacement therapy can be enrolled.
- Participate in another clinical study at the same time.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: IBI310 + IBI308
Participants will be treated with IBI310 in combination with IBI308
|
In this group, subjects will be given IBI310 3mg/kg IV Q3W in combination with IBI308 200mg IV Q3W for 4 cycles, then follow up a maintenance therapy performed with IBI310 3mg/kg IV Q12W in combination with IBI308 200mg IV Q3W until disease progression or loss of clinical benefit.
|
Experimental: IBI308
Participants will be treated with IBI308
|
In this group, subjects will be given IBI308 200mg IV Q3W until disease progression or loss of clinical benefit
|
Active Comparator: high-dose recombinant interferon a-2B
Participants will be treated with recombinant interferon a-2B
|
In this group, subjects will be given 15*10^9 U/m2/d recombinant interferon a-2B intravenously on days 1-5 weekly for 4 weeks.Then 9*10^9 U/m2/d recombinant interferon a-2B intravenously three times weekly for 48 weeks
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Recurrence-free survival rate
Time Frame: up to 5 years after enrollment
|
to evaluate the Recurrence free survival (RFS) of the patients with acral melanoma treated by IBI310 in Combination With IBI308 and high-Dose interferon
|
up to 5 years after enrollment
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Overall survival (OS)
Time Frame: up to 5 years after enrollment
|
to evaluate the Overall survival (OS) of the patients with acral melanoma treated by IBI310 in Combination With IBI308 and high-Dose interferon
|
up to 5 years after enrollment
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
April 17, 2020
Primary Completion (Actual)
February 28, 2023
Study Completion (Actual)
February 28, 2023
Study Registration Dates
First Submitted
February 18, 2020
First Submitted That Met QC Criteria
February 18, 2020
First Posted (Actual)
February 20, 2020
Study Record Updates
Last Update Posted (Estimate)
March 9, 2023
Last Update Submitted That Met QC Criteria
March 7, 2023
Last Verified
March 1, 2023
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CIBI310A301
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
No
Studies a U.S. FDA-regulated device product
No
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Acral Melanoma That Has Been Removed by Surgery
-
Daiichi Sankyo, Inc.PlexxikonTerminatedV600-mutated BRAF Unresectable Melanoma | V600-mutated BRAF Metastatic Melanoma | Stage III or Stage IV Metastatic Melanoma That Has Not Been Previously Treated With a Selective BRAF InhibitorUnited States, Germany, France
-
Arog Pharmaceuticals, Inc.CompletedAcute Myeloid Leukemia With FLT3 Activating Mutations That Has Relapsed or Been Refractory After One or More Prior TherapiesUnited States
Clinical Trials on IBI310+IBI308
-
Innovent Biologics (Suzhou) Co. Ltd.RecruitingAdvanced Biliary Tract CancerChina
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Innovent Biologics (Suzhou) Co. Ltd.Completed
-
Peking UniversityInnovent Biologics (Suzhou) Co. Ltd.UnknownAdvanced Gastric or Gastroesophageal Junction (GEJ) AdenocarcinomaChina
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedNSCLC (Non-small-cell Lung Cancer)China
-
Peking UniversityRecruitingNeuroendocrine NeoplasmChina
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced/Metastatic Solid MalignanciesUnited States
-
Shanghai Ninth People's Hospital Affiliated to...UnknownPrecancerous Conditions | Oral Cavity Cancer | Mouth NeoplasmChina
-
Innovent Biologics (Suzhou) Co. Ltd.CompletedAdvanced Solid TumorsChina
-
Innovent Biologics (Suzhou) Co. Ltd.Active, not recruitingAdvanced Hepatocellular CarcinomaChina